Galecto Dirección

Dirección controles de criterios 3/4

El CEO de Galecto es Hans Schambye , nombrado en Jan 2020, tiene una permanencia de 4.83 años. compensación anual total es $965.12K, compuesta por 52.4% salario y 47.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.16% de las acciones de la empresa, por valor de $11.79K. La antigüedad media del equipo directivo y de la junta directiva es de 3.5 años y 4.5 años, respectivamente.

Información clave

Hans Schambye

Chief Executive Officer (CEO)

US$965.1k

Compensación total

Porcentaje del salario del CEO	52.4%
Permanencia del CEO	4.8yrs
Participación del CEO	0.2%
Permanencia media de la dirección	3.5yrs
Promedio de permanencia en la Junta Directiva	4.5yrs

Actualizaciones recientes de la dirección

Recent updates

Galecto’s GB1211 to be studied for phase 2 trial in combination with pembrolizumab to treat cancer

Oct 19

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Oct 19

Galecto GAAP EPS of -$0.67 beats by $0.02

Jul 29

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Jun 30

Is Galecto (NASDAQ:GLTO) In A Good Position To Deliver On Growth Plans?

Mar 10

Galecto: Selling At Cash Value

Dec 19

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Nov 18

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Jul 07

Galecto EPS misses by $0.07

May 04

We Think Galecto (NASDAQ:GLTO) Can Afford To Drive Business Growth

Mar 23

Do Institutions Own Galecto, Inc. (NASDAQ:GLTO) Shares?

Jan 29

Galecto EPS misses by $41.65

Dec 11

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Hans Schambye en comparación con los beneficios de Galecto?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$21m
Jun 30 2024	n/a	n/a	-US$25m
Mar 31 2024	n/a	n/a	-US$31m
Dec 31 2023	US$965k	US$506k	-US$38m
Sep 30 2023	n/a	n/a	-US$46m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$58m
Dec 31 2022	US$1m	US$473k	-US$62m
Sep 30 2022	n/a	n/a	-US$61m
Jun 30 2022	n/a	n/a	-US$60m
Mar 31 2022	n/a	n/a	-US$55m
Dec 31 2021	US$3m	US$512k	-US$52m
Sep 30 2021	n/a	n/a	-US$42m
Jun 30 2021	n/a	n/a	-US$44m
Mar 31 2021	n/a	n/a	-US$43m
Dec 31 2020	US$4m	US$387k	-US$35m
Sep 30 2020	n/a	n/a	-US$57m
Jun 30 2020	n/a	n/a	-US$48m
Mar 31 2020	n/a	n/a	-US$42m
Dec 31 2019	US$479k	US$360k	-US$42m

Compensación vs. Mercado: La compensación total de Hans($USD965.12K) está por encima de la media de empresas de tamaño similar en el mercado US ($USD649.63K).

Compensación vs. Ingresos: La compensación de Hans ha sido consistente con los resultados de la empresa en el último año.

CEO

Hans Schambye (58 yo)

4.8yrs

Permanencia

US$965,115

Compensación

Dr. Hans T. Schambye, MD, Ph D, serves as Member of Board of Directors at BioInnovation Institute. Dr. Schambye is Co-Founder and has been Chief Executive Officer and Director at Galecto, Inc. since 2020 a...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Hans Schambye	Co-Founder	4.8yrs	US$965.12k	0.16% $ 11.8k
Garrett Winslow	Senior VP	3.5yrs	US$554.39k	0.012% $ 899.3
Ulf Nilsson	Co-Founder	no data	sin datos	sin datos
Hakon Leffler	Co-Founder	no data	sin datos	sin datos
Tariq Sethi	Co-Founder	no data	sin datos	sin datos
Lori Firmani	Interim Chief Financial Officer	less than a year	sin datos	sin datos

3.5yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de GLTO se considera experimentado (3.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Hans Schambye	Co-Founder	4.8yrs	US$965.12k	0.16% $ 11.8k
Carl Goldfischer	Independent Chairman of the Board	4.8yrs	US$155.19k	0.029% $ 2.2k
David Shapiro	Independent Director	4.5yrs	US$148.84k	0% $ 0
Amit Munshi	Independent Director	4.5yrs	US$78.85k	0.015% $ 1.1k
Anne Prener	Independent Director	3.8yrs	US$83.85k	0% $ 0
Jayson Donald Dallas	Independent Director	4yrs	US$86.35k	0% $ 0
Jonathan Fallowfield	Member of Clinical Advisory Board – Liver cirrhosis	no data	sin datos	sin datos
Adam Mead	Member of the Clinical Advisory Board - Myelofibrosis	no data	sin datos	sin datos
Aaron Gerds	Member of the Clinical Advisory Board - Myelofibrosis	no data	sin datos	sin datos
Claire Harrison	Member of the Clinical Advisory Board - Myelofibrosis	no data	sin datos	sin datos
John Mascarenhas	Member of the Clinical Advisory Board - Myelofibrosis	no data	sin datos	sin datos
Raajit Rampal	Member of the Clinical Advisory Board - Myelofibrosis	no data	sin datos	sin datos

4.5yrs

Permanencia media

61.5yo

Promedio de edad

Junta con experiencia: La junta directiva de GLTO se considera experimentada (4.5 años de antigüedad promedio).

Galecto Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Galecto, Inc Appoints Amy Wechsler to Its Board of Directors

Galecto, Inc., Annual General Meeting, Jun 20, 2024

Insufficient new directors

High number of new and inexperienced directors

High number of new directors

Galecto, Inc. Announces the Appointment of Dr. Anne Prener to Its Board of Directors

Recent updates

New minor risk - Shareholder dilution

Galecto, Inc Appoints Amy Wechsler to Its Board of Directors

New major risk - Market cap size

New major risk - Share price stability

Galecto Announces Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Galecto, Inc. Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

Galecto, Inc., Annual General Meeting, Jun 20, 2024

New major risk - Financial position

New minor risk - Share price stability

Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth?

Insufficient new directors

Galecto, Inc. Announces Positive Topline Results from A Phase 2A Trial of GB2064 for the Treatment of Myelofibrosis

Galecto, Inc. Presents Updated Clinical Data At ESMO Congress 2023 and Provides Update on Phase 1B/2A Gallant-1 Trial

Galecto Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Galecto, Inc. Proposes to Reduce Its Workforce by 29 People, or Approximately 70% of the Existing Headcount

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

New minor risk - Shareholder dilution

New major risk - Share price stability

New major risk - Financial position

Price target increased by 17% to US$12.00

Here's Why Galecto (NASDAQ:GLTO) Must Use Its Cash Wisely

Price target increased by 18% to US$10.25

Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely?

Price target decreased to US$8.33

High number of new and inexperienced directors

Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022

Galecto, Inc’s Galectin-3 Inhibitor GB1211 to Be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute

Galecto’s GB1211 to be studied for phase 2 trial in combination with pembrolizumab to treat cancer

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Galecto, Inc Announces Results from A Planned Intermediate Assessment of the Ongoing Phase 2A Trial of GB2064, a LOXL2 Inhibitor Product Candidate, for the Treatment of Myelofibrosis

Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal

Price target decreased to US$10.00

Galecto GAAP EPS of -$0.67 beats by $0.02

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Galecto Announces First Patient Enrolled in Phase 2 Trial of Gb1211 in Combination with Atezolizumab for First-Line Treatment of Nsclc

Price target decreased to US$11.00

High number of new directors

Galecto, Inc. Completes Enrollment in Global Phase 2B GALACTIC-1 Trial of GB0139 for the Treatment of IPF

Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Is Galecto (NASDAQ:GLTO) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$9.50

Price target decreased to US$11.67

Galecto Publishes Results Showing Safety and Efficacy of the Gb0139 Inhaled Galectin-3 Inhibitor in Hospitalized Covid-19 Patients on Standard of Care

Galecto Provides Enrollment Update on Phase 2a MYLOX-1 Trial and Reiterates Expected Timing of Multiple Data Readouts in 2022

Galecto: Selling At Cash Value

Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor Gb1211 in Liver Cirrhosis

Galecto, Inc. Announces First Patient Treated in Phase 2a Trial of the Oral LOXL2 Inhibitor Gb2064 in Myelofibrosis (The MYLOX-1 Trial)

Galecto Resumes Recruitment in Phase 2b Global GALACTIC-1 Trial of GB0139 for Idiopathic Pulmonary Fibrosis

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Galecto, Inc. Announces Preliminary Topline Results from Galectin-3 Inhibitor GB0139

Galecto EPS misses by $0.07

We Think Galecto (NASDAQ:GLTO) Can Afford To Drive Business Growth

Galecto, Inc. Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Study of GB0139 for Idiopathic Pulmonary Fibrosis: DSMB Recommends Study to Continue with Modifications

New 90-day low: US$11.99

Do Institutions Own Galecto, Inc. (NASDAQ:GLTO) Shares?

Galecto, Inc. Announces the Appointment of Dr. Anne Prener to Its Board of Directors

Galecto EPS misses by $41.65

Galecto, Inc. Appoints Dr. Jayson Dallas to Board of Directors

Galecto, Inc. has completed an IPO in the amount of $85.000005 million.

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta